Balancing Media Development with Patient Safety - - BioPharm International


Balancing Media Development with Patient Safety

BioPharm International Supplements

The Future of Media Development

Biopharmaceutical companies are beginning to take a responsible approach to media formulation, and significant effort is being invested in the development of well defined, animal-origin free alternatives. It is important, however, to establish actual risk when deciding the level of animal-origin free components beyond the primary level. If a critical or expensive bioproduct such as insulin is to be manufactured, then the biopharmaceutical manufacturer may well be justified in setting raw material specifications. Many are seeking secondary level animal-origin–free insulin despite the injectable being a primary level product.10 This shows that before considering the animal-origin–free level of a raw material, it is important to review all aspects of the process and determine the overall potential risk of the product.

A shift toward the universal use of chemically defined media is a beneficial step forward in the long term. Companies must be prepared for a change in regulatory guidelines, which may include a ban of animal-derived components from biologics manufacturing or stipulate a complete chemically detailed profile of raw materials used in the process. Either way, a chemically defined process must be the ultimate goal of all biopharmaceutical companies, helping them meet their goal of balancing media development with patient safety.

MICHELLE LEA, PhD, is a senior fermentation development scientist at Eden Biodesign Ltd, Liverpool, UK, +44 151 728 1750,


1. Lee K. A media design program for lactic acid production coupled with extraction by electrodialysis. Bioresource Technol. 2005;96:1505–10.

2. Grosvenor S. The role of media development in process optimization: An historical perspective. BioPharm Int. A Guide to Protein Production. 2008 Jun suppl;28–37.

3. Stanbury PF, Whitaker A, Hall SJ. Principles of fermentation technology. Oxford, UK: Butterworth-Heinmann Press; 2000; p. 74–90.

4. Hahn-Hägerdal B, Karhumaa K, Larsson CU, Gorwa-Grauslund M, Görgens J, van Zyl WH. Role of cultivation media in the development of yeast strains for large scale industrial use. Microb Cell Fact. 2005;4:31–46.

5. Helle SS, Murray A, Lam J, Cameron DR, Duff SJ. Xylose fermentation by genetically modified Saccharomyces cerevisiae 259ST in spent sulfite liquor. Bioresource Technol. 2004;92:163–171.

6. Van Niel EWJ, Hahn-Hägerdal B. Nutrient requirements of Lactococci in defined growth media. Appl Microbiol Biotecnol. 1999;52:617–27.

7. Hammet K, Kuchibhatla J, Hunt C, Holdread S, Brooks JW. Developing chemically defined media through DOE: complete optimization with increased protein production in less than 8 months. Cell Technologies for Cell Products. Springer. 2007; 683–91.

8. Ham RG. Clonal growth of mammalian cells in a chemically defined synthetic medium. Proc Natl Acad Sci. 1965;53:288–95.

9. Pamukcoglu T. A risk-based approach to establishing animal-component-free facilities. BioProcess Int. 2009 Dec;7(11):54–7.

10. Madigan LE, Donahue-Hjelle L, Nampalli SS, Stramaglia MJ. Strategies for sourcing animal-origin free cell culture media components. BioPharm Int. Guide to Outsourcing. 2009 Apr;34–37.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here